Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.205 USD | +1.83% | -11.92% | -35.32% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
10/05 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.32% | 2.68B | |
+29.78% | 48.16B | |
-0.75% | 41.73B | |
+44.02% | 41.03B | |
-5.31% | 28.77B | |
+10.47% | 25.59B | |
-22.49% | 18.96B | |
+9.06% | 12.92B | |
+28.64% | 12.03B | |
-2.42% | 11.77B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics Insider Sold Shares Worth $253,542, According to a Recent SEC Filing